FDA Flexible CMC Requirements for Cell and Gene Therapies: What Sponsors Need to Know

In this blog, Moira Frances explores the FDA’s formalization of a flexible CMC framework for cell and gene therapies, examining what has changed and how sponsors can apply this approach to de-risk development and support successful BLA submissions.